- Home
- PHAR vs UFCS Comparison
PHAR vs UFCS Comparison
Compare PHAR & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- UFCS
- Stock Information
- Founded
- PHAR 1988
- UFCS 1946
- Country
- PHAR Netherlands
- UFCS United States
- Employees
- PHAR N/A
- UFCS N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- UFCS Property-Casualty Insurers
- Sector
- PHAR Health Care
- UFCS Finance
- Exchange
- PHAR Nasdaq
- UFCS Nasdaq
- Market Cap
- PHAR 718.1M
- UFCS 666.1M
- IPO Year
- PHAR N/A
- UFCS N/A
- Fundamental
- Price
- PHAR $11.24
- UFCS $28.23
- Analyst Decision
- PHAR Strong Buy
- UFCS Buy
- Analyst Count
- PHAR 3
- UFCS 2
- Target Price
- PHAR $30.00
- UFCS $30.00
- AVG Volume (30 Days)
- PHAR 3.1K
- UFCS 88.8K
- Earning Date
- PHAR 05-08-2025
- UFCS 05-06-2025
- Dividend Yield
- PHAR N/A
- UFCS 2.25%
- EPS Growth
- PHAR N/A
- UFCS N/A
- EPS
- PHAR N/A
- UFCS 2.54
- Revenue
- PHAR $320,708,000.00
- UFCS $1,288,423,000.00
- Revenue This Year
- PHAR $13.31
- UFCS $11.31
- Revenue Next Year
- PHAR $7.68
- UFCS $10.61
- P/E Ratio
- PHAR N/A
- UFCS $11.20
- Revenue Growth
- PHAR 24.13
- UFCS 14.59
- 52 Week Low
- PHAR $6.65
- UFCS $18.04
- 52 Week High
- PHAR $11.07
- UFCS $31.70
- Technical
- Relative Strength Index (RSI)
- PHAR 69.87
- UFCS 49.42
- Support Level
- PHAR $10.02
- UFCS $27.98
- Resistance Level
- PHAR $10.89
- UFCS $28.71
- Average True Range (ATR)
- PHAR 0.23
- UFCS 0.82
- MACD
- PHAR 0.11
- UFCS 0.00
- Stochastic Oscillator
- PHAR 100.00
- UFCS 56.56
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.